Notably, we identified EGFR-related ligand-receptor pairs in CXCR1+ neutrophils and tumor cells, which were further enhanced in resistant samples, potentially contributing to EGFR-TKI resistance through sustained EGFR activation. The gene discussed is EGFR; the disease is neoplasm.